Open AccessMargetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A
Author(s) -
Daniel V.T. Catenacci,
YoonKoo Kang,
Harry H. Yoon,
Byoung Yong Shim,
S.T. Kim,
DoYoun Oh,
Alexander I. Spira,
S.V. Ulahannan,
E.J. Avery,
Patrick M. Boland,
Joseph Chao,
Hyun Cheol Chung,
F P Gardner,
Samuel J. Klempner,
K.-W. Lee,
Sang Cheul Oh,
J. Peguero,
Mohamad Bassam Sonbol,
Lin Shen,
Markus Moehler,
JongMu Sun,
D. Li,
Minori Koshiji Rosales,
H. Park
Publication year - 2022
Publication title -
esmo open
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.409
H-Index - 31
ISSN - 2059-7029
DOI - 10.1016/j.esmoop.2022.100563
Subject(s) - tolerability , medicine , regimen , cohort , trastuzumab , chemotherapy , oncology , gastroenterology , chemotherapy regimen , adverse effect , surgery , cancer , breast cancer
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom